Table 2.
Incidence of end point events
| Variable | P-years (1000) | Events | Incidence (1/1000) | 95% CI |
RR | 95% CI |
||
|---|---|---|---|---|---|---|---|---|
| Current statin usage | ||||||||
| No | 67.78 | 118 | 1.74 | 1.44 | 2.09 | |||
| Yes | 11.17 | 18 | 1.61 | 0.95 | 2.55 | 0.93 | 0.56 | 1.52 |
| Sex | ||||||||
| Male | 36.02 | 53 | 1.47 | 1.1 | 1.93 | |||
| Female | 42.93 | 83 | 1.93 | 1.54 | 2.4 | 1.31 | 0.93 | 1.85 |
| Age | ||||||||
| (0, 40] | 19.92 | 10 | 0.50 | 0.24 | 0.92 | |||
| (40, 50] | 20.22 | 15 | 0.74 | 0.41 | 1.22 | 1.48 | 0.66 | 3.29 |
| (50, 60] | 17.11 | 24 | 1.40 | 0.90 | 2.09 | 2.79 | 1.34 | 5.84 |
| (60, 70] | 11.05 | 28 | 2.53 | 1.68 | 3.66 | 5.05 | 2.45 | 10.39 |
| (70, Inf] | 10.65 | 59 | 5.54 | 4.22 | 7.15 | 11.04 | 5.65 | 21.58 |
| Insulin usage at baseline | ||||||||
| No | 77.83 | 133 | 1.71 | 1.43 | 2.03 | |||
| Yes | 1.12 | 3 | 2.68 | 0.55 | 7.83 | 1.57 | 0.50 | 4.92 |
| Blood glucose lowering drug | ||||||||
| No | 76.71 | 124 | 1.62 | 1.34 | 1.93 | |||
| Yes | 2.24 | 12 | 5.37 | 2.77 | 9.37 | 3.32 | 1.84 | 6.00 |
| Antithrombotic agent usage | ||||||||
| No | 76.7 | 120 | 1.56 | 1.30 | 1.87 | |||
| Yes | 2.25 | 16 | 7.11 | 4.06 | 11.55 | 4.55 | 2.70 | 7.66 |
| Antiplatelet agents usage | ||||||||
| No | 77.87 | 126 | 1.62 | 1.35 | 1.93 | |||
| Yes | 1.08 | 10 | 9.27 | 4.44 | 17.05 | 5.73 | 3.01 | 10.91 |
| Vitamin K antagonists usage | ||||||||
| No | 77.7 | 128 | 1.65 | 1.37 | 1.96 | |||
| Yes | 1.25 | 8 | 6.42 | 2.77 | 12.66 | 3.90 | 1.91 | 7.97 |
| Blood glucose (mmol/L) | ||||||||
| [2.4, 5.1] | 24.79 | 36 | 1.45 | 1.02 | 2.01 | |||
| (5.1, 5.6] | 23.93 | 31 | 1.30 | 0.88 | 1.84 | 0.89 | 0.55 | 1.44 |
| (5.6, 26.7] | 18.69 | 48 | 2.57 | 1.89 | 3.40 | 1.77 | 1.15 | 2.72 |
| Total cholesterol (mmol/L) | ||||||||
| [1.9, 5.4] | 23.71 | 36 | 1.52 | 1.06 | 2.10 | |||
| (5.4, 6.3] | 21.33 | 33 | 1.55 | 1.06 | 1.02 | 0.64 | 1.63 | 1.02 |
| (6.3, 11.7] | 22.38 | 46 | 2.06 | 1.50 | 1.35 | 0.88 | 2.09 | 1.35 |
| HDL cholesterol (mmol/L) | ||||||||
| [0.23, 1.13] | 22.39 | 45 | 2.01 | 1.46 | ||||
| (1.13, 1.45] | 22.45 | 33 | 1.47 | 1.01 | 0.73 | 0.47 | 1.15 | 0.73 |
| (1.45, 3.41] | 22.57 | 37 | 1.64 | 1.15 | 0.82 | 0.53 | 1.26 | 0.82 |
| LDL cholesterol (mmol/L) | ||||||||
| [0, 3.3] | 22.56 | 34 | 1.51 | 1.04 | ||||
| (3.3, 4.2] | 22.79 | 38 | 1.67 | 1.18 | 1.11 | 0.70 | 1.76 | 1.11 |
| (4.2, 8.8] | 22.06 | 43 | 1.95 | 1.41 | 1.29 | 0.82 | 2.03 | 1.29 |
| Triglycerides (mmol/L) | ||||||||
| [0.4, 1.1] | 26.16 | 30 | 1.15 | 0.77 | ||||
| (1.1, 1.7] | 21.84 | 45 | 2.06 | 1.50 | 1.80 | 1.13 | 2.85 | 1.80 |
| (1.7, 16.6] | 19.42 | 40 | 2.06 | 1.47 | 1.80 | 1.12 | 2.88 | 1.80 |
| Ratio HDL/cholesterol | ||||||||
| [3, 19] | 23.92 | 48 | 2.01 | 1.48 | ||||
| (19, 25.7] | 20.58 | 34 | 1.65 | 1.14 | 0.82 | 0.53 | 1.28 | 0.82 |
| (25.7, 56] | 22.91 | 33 | 1.44 | 0.99 | 0.72 | 0.46 | 1.12 | 0.72 |
| C reactive protein (mg/L) | ||||||||
| [0, 0.39] | 22.26 | 22 | 0.99 | 0.62 | ||||
| (0.39, 1.41] | 21.62 | 42 | 1.94 | 1.40 | 1.97 | 1.17 | 3.29 | 1.97 |
| (1.41, 191] | 20.53 | 40 | 1.95 | 1.39 | 1.97 | 1.17 | 3.32 | 1.97 |
| Vitamin D3 (nmol/L) | ||||||||
| [5, 36] | 20.55 | 35 | 1.70 | 1.19 | 2.37 | |||
| (36, 50] | 21.42 | 31 | 1.45 | 0.98 | 2.06 | 0.85 | 0.52 | 1.38 |
| (50, 134] | 21.15 | 37 | 1.75 | 1.23 | 2.41 | 1.03 | 0.65 | 1.63 |
| Homocysteine (µmol/L) | ||||||||
| [3.7, 9.7] | 22.15 | 18 | 0.81 | 0.48 | 1.29 | |||
| (9.7, 12.5] | 21.82 | 32 | 1.47 | 1.00 | 2.07 | 1.80 | 1.01 | 3.22 |
| (12.5, 111] | 19.16 | 53 | 2.77 | 2.07 | 3.62 | 3.40 | 1.99 | 5.81 |
| Insulin (mU/L) | ||||||||
| [1, 5] | 22.72 | 26 | 1.14 | 0.75 | 1.68 | |||
| (5, 9] | 22.67 | 45 | 1.99 | 1.45 | 2.66 | 1.73 | 1.07 | 2.81 |
| (92 200] | 19.64 | 33 | 1.68 | 1.16 | 2.36 | 1.47 | 0.88 | 2.00 |
RR with 95% CI based on univariate Poisson regression model.
Laboratory measurements in tertiles ‘[a,b)’ means that interval a–b is closed left and open right. The data on variables are collected at baseline.
HDL, high-density lipoprotein; LDL, low-density lipoprotein; RR, rate ratio.